In addition, we demonstrated that combined treatment with bevacizumab and/or CsA down-regulated both MMP-3 and MMP-13 expression and greatly decreased pterygium fibroblast migration, confirming that these activities are necessary for this process. This evidence concerns the gene MMP13 and pterygium.